Drug Information

Drug General Information
Drug ID
D02CZK
Former ID
DNCL002635
Drug Name
Karenitecin
Synonyms
Karenitecin (TN)
Drug Type
Small molecular drug
Indication Advanced ovarian cancer; Lung cancer [ICD9: 183, 162; ICD10:C56, C33-C34] Phase 3 [522031]
Company
BioNumerik Pharmaceuticals
Structure
Download
2D MOL

3D MOL
Formula
C25H28N2O4Si
Canonical SMILES
CCC1(C2=C(COC1=O)C(=O)N3CC4=C(C5=CC=CC=C5N=C4C3=C2)CC[S<br />i](C)(C)C)O
InChI
1S/C25H28N2O4Si/c1-5-25(30)19-12-21-22-17(13-27(21)23(28)18(19)14-31-24(25)29)15(10-11-32(2,3)4)16-8-6-7-9-20(16)26-22/h6-9,12,30H,5,10-11,13-14H2,1-4H3/t25-/m0/s1
InChIKey
POADTFBBIXOWFJ-VWLOTQADSA-N
PubChem Compound ID
148202
PubChem Substance ID
530668, 10249845, 11443149, 14906395, 46225149, 50873155, 57346730, 96026007, 104418481, 126681210, 135105770, 140587255, 172918703, 175427037, 184826536, 198949673, 223663599, 228436255, 241051100, 242534801, 246301288, 252215634
Target and Pathway
Target(s) Toposisomerase-1 Target Info Inhibitor [525703]
NetPath Pathway IL2 Signaling Pathway
PANTHER Pathway DNA replication
Pathway Interaction Database Caspase Cascade in Apoptosis
WikiPathways Integrated Pancreatic Cancer Pathway
References
Ref 522031ClinicalTrials.gov (NCT00477282) Karenitecin Versus Topotecan in Patients With Advanced Epithelial Ovarian Cancer. U.S. National Institutes of Health.
Ref 525703Characterization of protein kinase chk1 essential for the cell cycle checkpoint after exposure of human head and neck carcinoma A253 cells to a novel topoisomerase I inhibitor BNP1350. Mol Pharmacol.2000 Mar;57(3):453-9.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.